Summary:
SURPASS-CVOT is a Phase 3, event-driven study. This study will assess the effect of once weekly Tirzepatide, up to 15mg, on MACE-3, compared to once weekly dulaglutide 1.5 mg, when added to the standard of care in patients with Type 2 Diabetes with established cardiovascular disease (CVD).
Qualified Participants Must:
• Be at least 40 years of age
•
No cardiac events within the last 2 months
•
A1C at least 7.0
•
Be willing to self inject study medication once weekly
Qualified Participants May Receive:
- Study related procedures such as bloodwork, ECG, etc.
- Physical performed by a board certified physician
- Compensation for time and travel expenses